These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 8427450)

  • 41. Management of shock following acute myocardial infarction. Part I. Drug therapy.
    Kuhn LA
    Am Heart J; 1978 Apr; 95(4):529-34. PubMed ID: 636990
    [No Abstract]   [Full Text] [Related]  

  • 42. Effect of isoproterenol,l-norepinephrine, and intraaortic counterpulsation on hemodynamics and myocardial metabolism in shock following acute myocardial infarction.
    Mueller H; Ayres SM; Giannelli S; Conklin EF; Mazzara JT; Grace WJ
    Circulation; 1972 Feb; 45(2):335-51. PubMed ID: 5009478
    [No Abstract]   [Full Text] [Related]  

  • 43. Threatened reinfarction. Effective therapy using streptokinase with reversal of cardiogenic shock.
    Andrews WR; Arnold JM; Sibbald WJ
    Chest; 1990 Aug; 98(2):495-7. PubMed ID: 2376188
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Methylprednisolone in the complex theapy of shock in myocardial infarct].
    Gratsianskiĭ NA
    Kardiologiia; 1970 Dec; 10(12):45-53. PubMed ID: 5507776
    [No Abstract]   [Full Text] [Related]  

  • 45. [Effect of naloxone on beta-endorphin and insulin concentrations during glucose tolerance testing in patients with simple obesity].
    Krzyzanowska-Swiniarska B; Gruszczyńska M; Pilarska K; Widecka K; Czekalski S
    Endokrynol Pol; 1993; 44(4):517-29. PubMed ID: 8055820
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Free-radical lipid peroxidation in acute myocardial infarction complicated by cardiogenic shock].
    Rysmendiev AZh; Tukesheva BSh; Grabarova IP; Iskakov KM
    Kardiologiia; 1986 May; 26(5):37-40. PubMed ID: 3735916
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Activated protein C levels and outcome in patients with cardiogenic shock complicating acute myocardial infarction.
    Fellner B; Rohla M; Jarai R; Smetana P; Freynhofer MK; Egger F; Zorn G; Weiss TW; Huber K; Geppert A
    Eur Heart J Acute Cardiovasc Care; 2017 Jun; 6(4):348-358. PubMed ID: 26936869
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [High-dosage glucocorticoid therapy in acute heart infarct and in cardiogenic shock].
    Krosch H; Schäbitz J
    Z Gesamte Inn Med; 1977 Nov; 32(22):631-3. PubMed ID: 602316
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Naloxone and cardiogenic shock].
    Unzueta Merino MC; Bonnin O; Cabrera Ruiz JC; Villar Landeira JM
    Rev Esp Anestesiol Reanim; 1987; 34(6):446-9. PubMed ID: 3423375
    [No Abstract]   [Full Text] [Related]  

  • 50. [Clinical results with streptokinase therapy in cardiogenic shock].
    Vogel G; Fiehring H
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1972; 97(1):44-9. PubMed ID: 4114582
    [No Abstract]   [Full Text] [Related]  

  • 51. [Glucagon in the acute stage of myocardial infarct].
    Waremboug H; Bertrand ME; Ducloux G; Pauchant M; Ginestet A; Ketelers JY; Carre A; Delbecque H
    Arch Mal Coeur Vaiss; 1973 Apr; 66(4):449-56. PubMed ID: 4200209
    [No Abstract]   [Full Text] [Related]  

  • 52. [First-aid employment of intensain in acute myocardial infarction].
    Lokshina PL
    Kardiologiia; 1970 Dec; 10(12):34-7. PubMed ID: 5507773
    [No Abstract]   [Full Text] [Related]  

  • 53. Role of beta-endorphins in silent myocardial ischemia.
    Weidinger F; Hammerle A; Sochor H; Smetana R; Frass M; Glogar D
    Am J Cardiol; 1986 Sep; 58(6):428-30. PubMed ID: 2944365
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of naloxone on plasma adrenocorticotropin levels and beta-endorphin-like immunoreactivity in bilaterally adrenalectomized patients with Cushing's disease and in Addison's disease.
    Kasperlik-Załuska A; Jeske W; Migdalska B; Soszyński P; Wiśniewska-Woźniak T
    Acta Med Pol; 1986; 27(3-4):131-9. PubMed ID: 2833071
    [No Abstract]   [Full Text] [Related]  

  • 55. Growth-differentiation factor 15 and osteoprotegerin in acute myocardial infarction complicated by cardiogenic shock: a biomarker substudy of the IABP-SHOCK II-trial.
    Fuernau G; Poenisch C; Eitel I; de Waha S; Desch S; Schuler G; Adams V; Werdan K; Zeymer U; Thiele H
    Eur J Heart Fail; 2014 Aug; 16(8):880-7. PubMed ID: 24903195
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of patients with cardiogenic shock in the setting of acute myocardial infarction. Case reports.
    Gogorishvili I; Archvadze A; Kipiani V; Kipshidze N
    Georgian Med News; 2008 Sep; (162):51-3. PubMed ID: 18830031
    [TBL] [Abstract][Full Text] [Related]  

  • 57. B-type natriuretic peptide and its molecular precursor in myocardial infarction complicated by cardiogenic shock.
    Hejmdal A; Boesgaard S; Lindholm MG; Goetze JP
    J Card Fail; 2007 Apr; 13(3):184-8. PubMed ID: 17448415
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Progressive nature of myocardial injury in selected patients with cardiogenic shock.
    Gutovitz AL; Sobel BE; Roberts R
    Am J Cardiol; 1978 Mar; 41(3):469-75. PubMed ID: 626124
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Experimental pain thresholds and plasma beta-endorphin levels during exercise.
    Droste C; Greenlee MW; Schreck M; Roskamm H
    Med Sci Sports Exerc; 1991 Mar; 23(3):334-42. PubMed ID: 2020272
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Plasma beta-endorphin levels in silent or symptomatic myocardial ischemia].
    Astorri E; Renzulli FS; Franchini D; Donati GP
    Ann Ital Med Int; 1990; 5(2):100-5. PubMed ID: 2248856
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.